Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reaches third Alzheimer's milestone

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate.

In January 2007, Boehringer and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's nanobodies against a single disease target.

The collaboration has a potential value of $265m in upfront and milestone payments and undisclosed royalties on product sales.

Boehringer is responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

Dr Edwin Moses, chairman and chief executive of Ablynx, said: "We are delighted that Boehringer Ingelheim is making further progress with the nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012."

It is the second milestone payment that Ablynx has received as part of its Alzheimer's research collaboration with Boehringer.

30th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics